This product(s) resides on a APICMO contract.
We have the ability to produce, synthesize and manufacture large quantities of 4-Chloro-6,7-dimethoxyquinazoline(13790-39-1) with quality control system under CGMP manufacturing regulations.
4-Chloro-6,7-dimethoxyquinazoline (13790-39-1) video
Patients with non-small-cell lung cancer (NSCLC) with somatic activating mutations of the epidermal growth factor receptor gene (EGFR mutations) generally respond to EGFR tyrosine kinase inhibitors (EGFR-TKIs). β-Catenin is a key component of the Wnt/β-Catenin signal and is an important oncogene that is involved in pathogenesis and progression of malignant tumors, especially cancer stem cells. It was found that EGFR-mutated NSCLC cell lines exhibited a high expression level of β-Catenin, compared with cell lines with the wild-type EGFR gene, and XAV939 (a β-Catenin inhibitor) enhanced the sensitivities to EGFR-TKI in EGFR-mutated NSCLC cell lines.
In EGFR-mutated NSCLC cell lines with acquired resistance threonine-to-methionine mutation in codon 790 (T790M) mutation, XAV939 enhanced the sensitivity of the cells to an irreversible EGFR-TKI but not a reversible EGFR-TKI. The combination of XAV939 and EGFR-TKIs strongly inhibited the β-Catenin signal and strongly decreased the phosphorylation of EGFR, compared with the use of EGFR-TKIs alone, suggesting an interaction between EGFR and the β-Catenin signal. The stem cell-like properties of the EGFR-mutated cell line carrying the T790M mutation were inhibited by XAV939 and BIBW2992 (an irreversible EGFR-TKI). Furthermore, the stem cell-like properties were strongly inhibited by a combination of both the agents. A xenograft study demonstrated that β-Catenin knockdown enhanced the antitumor effect of BIBW2992 in the EGFR-mutated NSCLC cell line carrying the T790M mutation. Conclusion: The findings indicate that β-Catenin might be a novel therapeutic target in EGFR-mutated NSCLC carrying the T790M mutation.
|CAS Min %||95.0|
|CAS Max %||100.0|
|Chemical Name or Material||4-Chloro-6,7-dimethoxyquinazoline|
|Physical Form||Powder or Chunks|
|Molecular Weight (g/mol)||224.65|
|Color||White or almost white power|
4-Chloro-6,7-dimethoxyquinazoline(13790-39-1) Safety and Handling
(13790-39-1) Hazard description:
♦ Causes skin irritation.
♦ Causes serious eye irritation.
♦ May cause respiratory irritation.
(13790-39-1) Precautionary statement:
♦ Avoid breathing dust/fume/gas/mist/vapors/spray.
♦ Wear protective gloves/protective clothing/eye protection/face protection.
♦ IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
♦ IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing.
♦ Store locked up.
♦ Dispose of contents/container in accordance with local/regional/national/international regulations.
WARNING: The information provided on this web site was developed in compliance with European Union (EU) regulations and is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guide for safe handling and use. It is not to be considered as either a warranty or quality specification.
R K Narla; X P Liu; D E Myers; and F M Uckun. 4-(3′-Bromo-4’hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin Cancer Res. 1988, 41405.
Chappie, T.A, et.al. Discovery of a Series of 6,7-Dimethoxy-4-pyrrolidylquinazoline PDE10A Inhibitors†.J. Med. Chem. 2007 , 50(2), 182-185.
4-Chloro-6,7-dimethoxyquinazoline(13790-39-1) Technical Service:
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
4-Chloro-6,7-dimethoxyquinazoline(13790-39-1) Bulk Ordering & Pricing:
Need larger quantities for your development, manufacturing or research applications?